TY - JOUR
T1 - Does the type of cryoprobe affect oncological and functional outcomes in men with clinically localized prostate cancer treated with primary whole gland prostate cryoablation?
AU - Taha, Tarek
AU - Tan, Wei Phin
AU - Elshafei, Ahmed
AU - Aminsharifi, Alireza
AU - Given, Robert
AU - Cher, Michael L.
AU - Polascik, Thomas J.
N1 - Funding Information:
The COLD registry is a multi-institutional, prospectively collected, web-based database of patients with localized and locally recurrent prostate cancer treated with primary and salvage cryotherapy. The registry was sponsored by Endocare (Austin, TX), and the database was maintained by an independent research company (Watermark Research Partners, Indianapolis, IN). The COLD registry was designed to collect and report the outcomes of cryoablation from 37 different community and academic centers in a systematic manner. The COLD registry is supervised by a scientific board of urologists, and an independent audit of scientific data is conducted yearly at randomly chosen centers to ensure the quality and accuracy of data. All participating sites have approval from their institutional review board before submission of any data to the registry database. Moreover, the registry has a global institutional review board protocol since 2006.
Publisher Copyright:
© 2021 S. Karger AG. All rights reserved.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Background:This study aimed to compare the oncological and functional outcomes of primary whole gland cryoablation of the prostate using the variable ice cryoprobe (V-Probe®) and the conventional fixed-size ice probe.Materials and methods:We reviewed the Cryo On-Line Data Registry for men who were treated with primary whole gland prostate cryoablation from 2000 through 2017. A multivariate Cox proportional hazards model was used to compare timing to biochemical recurrence between the V-Probe®and fixed-size ice probe after adjusting for preoperative prostate-specific antigen (PSA), neoadjuvant androgen deprivation therapy, preoperative Gleason score, and preoperative T stage.Results:A total of 1124 men were included. Median age, Gleason score, and pretreatment PSA were 70 years (interquartile range [IQR]: 65-74 years), 7 (IQR: 6-7) and 5.9 ng/mL (IQR: 4.6-8.1 ng/mL), respectively. The median follow-up time was 25.0 months (IQR: 11.2-48.6 months). V-Probes®were used in 269 (23.9%) cases and fixed-size ice probes in 858 (76.1%) cases. After adjusting for clinical T stage, PSA, neoadjuvant androgen deprivation therapy and preoperative Gleason score, on the multivariate Cox regression model, we found that there was no significant difference between the type of probe and timing to biochemical recurrence (p = 0.35). On multivariate logistic regression, using the V-Probe®was associated with a 91% increase in postoperative urinary retention compared to the fixed-size ice probe (p = 0.003).Conclusions:The use of the V-Probe®versus conventional fixed-size ice probe was not associated with a difference in biochemical recurrence in patients undergoing primary cryoablation of the prostate.
AB - Background:This study aimed to compare the oncological and functional outcomes of primary whole gland cryoablation of the prostate using the variable ice cryoprobe (V-Probe®) and the conventional fixed-size ice probe.Materials and methods:We reviewed the Cryo On-Line Data Registry for men who were treated with primary whole gland prostate cryoablation from 2000 through 2017. A multivariate Cox proportional hazards model was used to compare timing to biochemical recurrence between the V-Probe®and fixed-size ice probe after adjusting for preoperative prostate-specific antigen (PSA), neoadjuvant androgen deprivation therapy, preoperative Gleason score, and preoperative T stage.Results:A total of 1124 men were included. Median age, Gleason score, and pretreatment PSA were 70 years (interquartile range [IQR]: 65-74 years), 7 (IQR: 6-7) and 5.9 ng/mL (IQR: 4.6-8.1 ng/mL), respectively. The median follow-up time was 25.0 months (IQR: 11.2-48.6 months). V-Probes®were used in 269 (23.9%) cases and fixed-size ice probes in 858 (76.1%) cases. After adjusting for clinical T stage, PSA, neoadjuvant androgen deprivation therapy and preoperative Gleason score, on the multivariate Cox regression model, we found that there was no significant difference between the type of probe and timing to biochemical recurrence (p = 0.35). On multivariate logistic regression, using the V-Probe®was associated with a 91% increase in postoperative urinary retention compared to the fixed-size ice probe (p = 0.003).Conclusions:The use of the V-Probe®versus conventional fixed-size ice probe was not associated with a difference in biochemical recurrence in patients undergoing primary cryoablation of the prostate.
UR - http://www.scopus.com/inward/record.url?scp=85121327199&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121327199&partnerID=8YFLogxK
U2 - 10.1097/CU9.0000000000000015
DO - 10.1097/CU9.0000000000000015
M3 - Article
C2 - 34168524
AN - SCOPUS:85121327199
VL - 15
SP - 79
EP - 84
JO - Current Urology
JF - Current Urology
SN - 1661-7649
IS - 2
ER -